Asymmetric synthesis of the sulfoxide metabolite of ON-579 by the Kagan protocol

Article abstract of DOI:10.1016/S0960-894X(97)00456-3

A synthesis of both enantiomers of bio-active metabolite of 0N-579; 4-[2-(4-chlorophenyl- sulfonylamino)-ethylsulfinyl]-2,6-difluorophnoxyacetic acid was accomplished by the asymmetric oxidation of 0N-579 methyl-ester followed by hydrolysis. Difference in TXA₂ receptor antagonizing activity was noted for the enantiomers in an U46619-induced rabbit platelet aggregation inhibitory activity.